# Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

> **NCT02601274** · PHASE1 · TERMINATED · sponsor: **Hutchison Medipharma Limited** · enrollment: 33 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Theliatinib

## Key facts

- **NCT ID:** NCT02601274
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** the change of clinical development plan
- **Last updated:** 2019-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601274, "Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02601274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*